1. Phylogeny  
Serine/threonine‐protein kinase MRCK beta (gene CDC42BPB; UniProt Q9Y5S2) belongs to a highly conserved subgroup of the AGC kinase superfamily that is classified within the DMPK‐related kinase family. MRCK beta clusters phylogenetically with its paralogs MRCK alpha and MRCK gamma, as well as with related kinases such as DMPK and the Rho‐associated kinases (ROCK1 and ROCK2), all of which are evolutionarily derived from early eukaryotic ancestors and are present across diverse metazoan species (leung1998myotonicdystrophykinaserelated pages 1-2, zihni2021mrckamaster pages 1-4). Its distribution is ubiquitous in mammalian tissues, and orthologs of MRCK beta can be identified in species ranging from invertebrates to humans, underscoring its preservation throughout animal evolution (zihni2021mrckamaster pages 1-4, zhao2015myotonicdystrophykinaserelated pages 1-2). The evolutionary relationship of MRCK beta with other Rho GTPase effectors is further supported by its shared domain architecture with proteins such as myotonic dystrophy protein kinase (DMPK) and ROCK kinases, reflecting a common ancestral origin of Rho family–regulated signaling pathways (garcia2006molecularinsightsinto pages 32-35, leung1998myotonicdystrophykinaserelated pages 1-2).

2. Reaction Catalyzed  
MRCK beta catalyzes the transfer of a phosphate group from ATP to serine and/or threonine residues present on target substrate proteins. The enzymatic reaction may be formally represented as follows: ATP + [protein]–OH → ADP + [protein]–O–phosphate + H⁺. This kinase‐mediated phosphorylation reaction is central to its role in modulating the contractile and regulatory functions of proteins involved in cytoskeletal dynamics (zhao2015myotonicdystrophykinaserelated pages 1-2).

3. Cofactor Requirements  
The catalytic activity of MRCK beta, as is common with serine/threonine kinases from the AGC family, depends on the presence of divalent cations. In particular, Mg²⁺ is required as a cofactor to facilitate ATP binding and phosphoryl transfer reactions by coordinating the phosphate groups of ATP within the active site of the kinase (zhao2015myotonicdystrophykinaserelated pages 1-2).

4. Substrate Specificity  
MRCK beta exhibits substrate specificity for proteins that play critical roles in the regulation of the actomyosin cytoskeleton. It phosphorylates regulatory proteins including the myosin regulatory light chain (MLC2/MYL9) at serine residues (e.g., Ser19), an event that is essential for the activation of myosin II and subsequent actin filament contraction (leung1998myotonicdystrophykinaserelated pages 9-10, clayton2020targetingrhogtpase pages 7-8). In addition, MRCK beta phosphorylates myosin phosphatase target subunits such as PPP1R12A (also known as MYPT1) and PPP1R12C, thereby modulating the activity of the myosin light chain phosphatase complex (clayton2020targetingrhogtpase pages 7-8). Through these phosphorylation events, MRCK beta is positioned as a key regulator of lamellar actomyosin retrograde flow, which is necessary for cell protrusion and migration. Although a precise consensus substrate motif for MRCK beta has not been fully defined in the literature provided, its substrate preferences are closely associated with regions of the target proteins that facilitate regulation of actomyosin contractility (unbekandt2014theactinmyosinregulatory pages 1-2, zhao2015myotonicdystrophykinaserelated pages 1-2).

5. Structure  
MRCK beta is a multidomain protein whose architecture underlies both its catalytic activity and its regulation via interactions with upstream signaling molecules. At the N-terminus, it harbors a highly conserved protein kinase domain responsible for ATP binding and phosphoryl transfer; within this domain, key catalytic residues such as a conserved lysine (e.g., Lys105) are essential for enzymatic activity, a feature that is common among serine/threonine kinases (unbekandt2020thecdc42effector pages 3-4). Adjacent to the kinase domain, MRCK beta contains a C1 (protein kinase C conserved region 1) domain that binds diacylglycerol analogs such as phorbol esters, facilitating membrane association that is important for its subcellular localization (clayton2020targetingrhogtpase pages 7-8, zihni2021mrckamaster pages 4-6). Following the C1 domain, a pleckstrin homology (PH)-like domain is present; this domain is implicated in lipid binding and contributes to the recruitment of MRCK beta to specific membrane microdomains where active signaling occurs (zihni2021mrckamaster pages 1-4). MRCK beta also contains a citron homology (CH) domain, which is thought to mediate interactions with cytoskeletal proteins or adaptor molecules necessary for substrate docking (kale2015invitrocharacterization pages 22-27, leung1998myotonicdystrophykinaserelated pages 1-2). At its extreme C-terminus, a CDC42/Rac interactive binding (CRIB) domain is found; this domain is responsible for the specific interaction with the active, GTP-bound forms of CDC42 (and under some conditions Rac1), thus linking receptor-mediated activation of small GTPases to the catalytic activation of MRCK beta (leung1998myotonicdystrophykinaserelated pages 1-2, zhao2015myotonicdystrophykinaserelated pages 1-2). Structural studies have revealed that MRCK beta adopts an active conformation within its catalytic domain that is characterized by an ordered activation loop and a well‐positioned C‐helix, features that are necessary for efficient phosphoryl transfer (unbekandt2020thecdc42effector pages 3-4). An autophosphorylation site on threonine 1108 has been identified in MRCK beta; although mutation of this residue does not appear to significantly alter kinase activity or subcellular localization, its presence provides a useful biochemical marker for enzyme activity (unbekandt2020thecdc42effector pages 7-9).

6. Regulation  
The regulation of MRCK beta is mediated by multiple mechanisms that converge to control its activity and subcellular distribution. Binding of GTP-bound CDC42 via the CRIB domain is a primary regulatory event that triggers the recruitment of MRCK beta to membrane compartments where actin remodeling is active (leung1998myotonicdystrophykinaserelated pages 1-2, zihni2021mrckamaster pages 4-6). In addition to direct binding, MRCK beta undergoes autophosphorylation on key residues such as threonine 1108; while experimental mutagenesis studies have shown that alteration of this residue does not significantly affect catalytic function, its phosphorylation state may nevertheless serve as an indicator of kinase activation (unbekandt2020thecdc42effector pages 7-9). Post-translational modifications, including potential phosphorylation by upstream kinases and caspase-mediated cleavage during apoptosis, further contribute to the dynamic regulation of MRCK beta, although the precise pattern of such modifications is not fully delineated in the current literature (zihni2021mrckamaster pages 6-8, leung1998myotonicdystrophykinaserelated pages 9-10). Moreover, interactions with adaptor proteins such as FAM89B/LRAP25 and MYO18A have been implicated in the targeting of MRCK beta to specific subcellular sites, thereby enhancing its ability to modulate lamellipodial actomyosin dynamics and to facilitate the activation of downstream effectors such as LIMK1 (clayton2020targetingrhogtpase pages 7-8, unbekandt2014anovelsmallmolecule pages 11-12). These mechanisms work in concert to ensure that MRCK beta activity is spatially and temporally coordinated with cytoskeletal remodeling events, particularly during processes of cell migration and morphogenesis (unbekandt2014theactinmyosinregulatory pages 7-8).

7. Function  
MRCK beta functions as a pivotal effector of CDC42-driven signaling pathways that regulate actin cytoskeletal reorganization and cell migration. It phosphorylates key substrates, including myosin regulatory light chain (MLC2/MYL9) at residues such as Ser19, to promote the contractile activity of nonmuscle myosin II; this phosphorylation event is crucial for the generation of contractile forces required for cell protrusion and retraction (leung1998myotonicdystrophykinaserelated pages 9-10, clayton2020targetingrhogtpase pages 7-8). In addition, MRCK beta phosphorylates PPP1R12A, an essential regulatory subunit of the myosin light chain phosphatase complex, thereby contributing to sustained myosin light chain phosphorylation and actomyosin contractility (clayton2020targetingrhogtpase pages 7-8). Through its regulation of these substrates, MRCK beta modulates lamellar actomyosin retrograde flow, a process that is critical for the formation of lamellipodia and for directional cell migration (unbekandt2014anovelsmallmolecule pages 7-10). Furthermore, in coordination with proteins such as MYO18A and FAM89B/LRAP25, MRCK beta participates in the targeting and activation of LIMK1 at the lamellipodium, which in turn phosphorylates and inactivates cofilin to stabilize F-actin structures (clayton2020targetingrhogtpase pages 7-8, unbekandt2014theactinmyosinregulatory pages 1-2). The expression pattern of MRCK beta is generally ubiquitous, yet its activity is particularly critical in epithelial cells where it contributes to the regulation of apical membrane dynamics and epithelial polarity (zihni2021mrckamaster pages 1-4, zihni2021mrckamaster pages 6-8). In the context of cancer, elevated MRCK beta signaling has been associated with enhanced cell invasion and metastasis, and its kinase activity is being actively explored as a potential therapeutic target for anti‐metastatic strategies (unbekandt2014anovelsmallmolecule pages 14-15, clayton2020targetingrhogtpase pages 12-12).

8. Other Comments  
Several small-molecule inhibitors have been identified that target MRCK beta, among which BDP5290 is notable for its potency and selectivity; such inhibitors have been demonstrated to effectively block MRCK-mediated MLC phosphorylation and attenuate cancer cell invasion in vitro (unbekandt2014anovelsmallmolecule pages 10-11, unbekandt2014anovelsmallmolecule pages 14-15). Additional compounds, including chelerythrine, have been reported to inhibit MRCK activity; however, these agents often display off-target effects that complicate their use as selective chemical probes (zhao2015myotonicdystrophykinaserelated pages 3-4, prudnikova2015molecularpathwaystargeting pages 9-11). In terms of disease associations, MRCK beta overactivity has been linked to increased tumor cell motility, invasion, and metastasis, rendering it an attractive target for therapeutic intervention in cancer (clayton2020targetingrhogtpase pages 12-12, prudnikova2015molecularpathwaystargeting pages 9-11). To date, no disease-causing mutations specific to MRCK beta have been definitively reported; its pathogenic role appears to be primarily associated with aberrant regulation in oncogenic signaling pathways rather than with inherited genetic defects. The development of selective inhibitors and the use of phospho-specific antibodies are expected to further refine the understanding of MRCK beta’s role in cytoskeletal regulation and its potential as a drug target (unbekandt2020thecdc42effector pages 7-9, zihni2021mrckamaster pages 6-8).

9. References  
1. Clayton, N. S. and Ridley, A. J. (2020). Targeting Rho GTPase signalling networks in cancer. Frontiers in Cell and Developmental Biology, Apr 2020, doi:10.3389/fcell.2020.00222 (clayton2020targetingrhogtpase pages 7-8, clayton2020targetingrhogtpase pages 12-12).  
2. Leung, T., Chen, X.-Q., Tan, I., Manser, E., and Lim, L. (1998). Myotonic dystrophy kinase-related cdc42-binding kinase acts as a cdc42 effector in promoting cytoskeletal reorganization. Molecular and Cellular Biology, Jan 1998, doi:10.1128/mcb.18.1.130 (leung1998myotonicdystrophykinaserelated pages 1-2, leung1998myotonicdystrophykinaserelated pages 9-10).  
3. Unbekandt, M., Croft, D. R., Crighton, D., Mezna, M., McArthur, D., McConnell, P., Schüttelkopf, A. W., Belshaw, S., Pannifer, A., Sime, M., Bower, J., Drysdale, M., and Olson, M. F. (2014). A novel small-molecule MRCK inhibitor blocks cancer cell invasion. Cell Communication and Signaling, Oct 2014, doi:10.1186/s12964-014-0054-x (unbekandt2014anovelsmallmolecule pages 1-2, unbekandt2014anovelsmallmolecule pages 11-12, unbekandt2014anovelsmallmolecule pages 12-13, unbekandt2014anovelsmallmolecule pages 2-4, unbekandt2014anovelsmallmolecule pages 7-10, unbekandt2014anovelsmallmolecule pages 14-15).  
4. Unbekandt, M. and Olson, M. F. (2014). The actin-myosin regulatory MRCK kinases: regulation, biological functions and associations with human cancer. Journal of Molecular Medicine, Feb 2014, doi:10.1007/s00109-014-1133-6 (unbekandt2014theactinmyosinregulatory pages 1-2, unbekandt2014theactinmyosinregulatory pages 7-8).  
5. Zhao, Z.-S. and Manser, E. (2015). Myotonic dystrophy kinase-related cdc42-binding kinases (MRCK), the ROCK-like effectors of cdc42 and rac1. Small GTPases, Apr 2015, doi:10.1080/21541248.2014.1000699 (zhao2015myotonicdystrophykinaserelated pages 1-2, zhao2015myotonicdystrophykinaserelated pages 2-3, zhao2015myotonicdystrophykinaserelated pages 6-7, zhao2015myotonicdystrophykinaserelated pages 7-7).  
6. Unbekandt, M., Lilla, S., Zanivan, S., and Olson, M. F. (2020). The cdc42 effector protein MRCKβ autophosphorylates on threonine 1108. Small GTPases, Jan 2020, doi:10.1080/21541248.2018.1564472 (unbekandt2020thecdc42effector pages 1-3, unbekandt2020thecdc42effector pages 3-4, unbekandt2020thecdc42effector pages 4-7, unbekandt2020thecdc42effector pages 7-9, unbekandt2020thecdc42effector pages 9-10).  
7. Zihni, C. (2021). MRCK: a master regulator of tissue remodeling or another ‘rock’ in the epithelial block? Tissue Barriers, May 2021, doi:10.1080/21688370.2021.1916380 (zihni2021mrckamaster pages 1-4, zihni2021mrckamaster pages 4-6, zihni2021mrckamaster pages 6-8, zihni2021mrckamaster pages 8-9).  
8. Elkins, J. M., Amos, A., Niesen, F. H., Pike, A. C. W., Fedorov, O., and Knapp, S. (2009). Structure of dystrophia myotonica protein kinase. Protein Science, Apr 2009, doi:10.1002/pro.82 (elkins2009structureofdystrophia pages 1-2).  
9. Garcia, et al. (2006). Molecular insights into the regulatory interactions of Dystrophia myotonica protein kinase. [Dissertation/Monograph], 2006 (garcia2006molecularinsightsinto pages 32-35, garcia2006molecularinsightsinto pages 35-39, garcia2006molecularinsightsinto pages 51-55, garcia2006molecularinsightsinto pages 68-72).  
10. Wansink, D. G., van Herpen, R. E. M. A., Coerwinkel-Driessen, M. M., Groenen, P. J. T. A., Hemmings, B. A., and Wieringa, B. (2003). Alternative splicing controls myotonic dystrophy protein kinase structure, enzymatic activity, and subcellular localization. Molecular and Cellular Biology, Aug 2003, doi:10.1128/mcb.23.16.5489-5501.2003 (wansink2003alternativesplicingcontrols pages 1-2).  
11. Prudnikova, T. Y., Rawat, S. J., and Chernoff, J. (2015). Molecular pathways: targeting the kinase effectors of Rho-family GTPases. Clinical Cancer Research, Jan 2015, doi:10.1158/1078-0432.ccr-14-0827 (prudnikova2015molecularpathwaystargeting pages 1-3, prudnikova2015molecularpathwaystargeting pages 9-11).

References

1. (clayton2020targetingrhogtpase pages 7-8): Natasha S. Clayton and Anne J. Ridley. Targeting rho gtpase signaling networks in cancer. Frontiers in Cell and Developmental Biology, Apr 2020. URL: https://doi.org/10.3389/fcell.2020.00222, doi:10.3389/fcell.2020.00222. This article has 183 citations and is from a peer-reviewed journal.

2. (kale2015invitrocharacterization pages 22-27): VP Kale. In vitro characterization of dj4, a novel inhibitor of rock and mrck kinases, as an anticancer agent. Unknown journal, 2015.

3. (leung1998myotonicdystrophykinaserelated pages 1-2): Thomas Leung, Xiang-Qun Chen, Ivan Tan, Edward Manser, and Louis Lim. Myotonic dystrophy kinase-related cdc42-binding kinase acts as a cdc42 effector in promoting cytoskeletal reorganization. Molecular and Cellular Biology, 18:130-140, Jan 1998. URL: https://doi.org/10.1128/mcb.18.1.130, doi:10.1128/mcb.18.1.130. This article has 373 citations and is from a domain leading peer-reviewed journal.

4. (unbekandt2014anovelsmallmolecule pages 1-2): Mathieu Unbekandt, Daniel R Croft, Diane Crighton, Mokdad Mezna, Duncan McArthur, Patricia McConnell, Alexander W Schüttelkopf, Simone Belshaw, Andrew Pannifer, Mairi Sime, Justin Bower, Martin Drysdale, and Michael F Olson. A novel small-molecule mrck inhibitor blocks cancer cell invasion. Cell Communication and Signaling, Oct 2014. URL: https://doi.org/10.1186/s12964-014-0054-x, doi:10.1186/s12964-014-0054-x. This article has 73 citations and is from a peer-reviewed journal.

5. (unbekandt2014anovelsmallmolecule pages 11-12): Mathieu Unbekandt, Daniel R Croft, Diane Crighton, Mokdad Mezna, Duncan McArthur, Patricia McConnell, Alexander W Schüttelkopf, Simone Belshaw, Andrew Pannifer, Mairi Sime, Justin Bower, Martin Drysdale, and Michael F Olson. A novel small-molecule mrck inhibitor blocks cancer cell invasion. Cell Communication and Signaling, Oct 2014. URL: https://doi.org/10.1186/s12964-014-0054-x, doi:10.1186/s12964-014-0054-x. This article has 73 citations and is from a peer-reviewed journal.

6. (unbekandt2014anovelsmallmolecule pages 12-13): Mathieu Unbekandt, Daniel R Croft, Diane Crighton, Mokdad Mezna, Duncan McArthur, Patricia McConnell, Alexander W Schüttelkopf, Simone Belshaw, Andrew Pannifer, Mairi Sime, Justin Bower, Martin Drysdale, and Michael F Olson. A novel small-molecule mrck inhibitor blocks cancer cell invasion. Cell Communication and Signaling, Oct 2014. URL: https://doi.org/10.1186/s12964-014-0054-x, doi:10.1186/s12964-014-0054-x. This article has 73 citations and is from a peer-reviewed journal.

7. (unbekandt2014anovelsmallmolecule pages 2-4): Mathieu Unbekandt, Daniel R Croft, Diane Crighton, Mokdad Mezna, Duncan McArthur, Patricia McConnell, Alexander W Schüttelkopf, Simone Belshaw, Andrew Pannifer, Mairi Sime, Justin Bower, Martin Drysdale, and Michael F Olson. A novel small-molecule mrck inhibitor blocks cancer cell invasion. Cell Communication and Signaling, Oct 2014. URL: https://doi.org/10.1186/s12964-014-0054-x, doi:10.1186/s12964-014-0054-x. This article has 73 citations and is from a peer-reviewed journal.

8. (unbekandt2014theactinmyosinregulatory pages 1-2): Mathieu Unbekandt and Michael F. Olson. The actin-myosin regulatory mrck kinases: regulation, biological functions and associations with human cancer. Journal of Molecular Medicine, 92:217-225, Feb 2014. URL: https://doi.org/10.1007/s00109-014-1133-6, doi:10.1007/s00109-014-1133-6. This article has 99 citations.

9. (unbekandt2014theactinmyosinregulatory pages 7-8): Mathieu Unbekandt and Michael F. Olson. The actin-myosin regulatory mrck kinases: regulation, biological functions and associations with human cancer. Journal of Molecular Medicine, 92:217-225, Feb 2014. URL: https://doi.org/10.1007/s00109-014-1133-6, doi:10.1007/s00109-014-1133-6. This article has 99 citations.

10. (zhao2015myotonicdystrophykinaserelated pages 1-2): Zhuo-shen Zhao and E. Manser. Myotonic dystrophy kinase-related cdc42-binding kinases (mrck), the rock-like effectors of cdc42 and rac1. Small GTPases, 6:81-88, Apr 2015. URL: https://doi.org/10.1080/21541248.2014.1000699, doi:10.1080/21541248.2014.1000699. This article has 78 citations and is from a peer-reviewed journal.

11. (zhao2015myotonicdystrophykinaserelated pages 2-3): Zhuo-shen Zhao and E. Manser. Myotonic dystrophy kinase-related cdc42-binding kinases (mrck), the rock-like effectors of cdc42 and rac1. Small GTPases, 6:81-88, Apr 2015. URL: https://doi.org/10.1080/21541248.2014.1000699, doi:10.1080/21541248.2014.1000699. This article has 78 citations and is from a peer-reviewed journal.

12. (zhao2015myotonicdystrophykinaserelated pages 6-7): Zhuo-shen Zhao and E. Manser. Myotonic dystrophy kinase-related cdc42-binding kinases (mrck), the rock-like effectors of cdc42 and rac1. Small GTPases, 6:81-88, Apr 2015. URL: https://doi.org/10.1080/21541248.2014.1000699, doi:10.1080/21541248.2014.1000699. This article has 78 citations and is from a peer-reviewed journal.

13. (garcia2006molecularinsightsinto pages 32-35): Molecular insights into the regulatory interactions of Dystrophia myotonica protein kinase

14. (garcia2006molecularinsightsinto pages 35-39): Molecular insights into the regulatory interactions of Dystrophia myotonica protein kinase

15. (garcia2006molecularinsightsinto pages 51-55): Molecular insights into the regulatory interactions of Dystrophia myotonica protein kinase

16. (leung1998myotonicdystrophykinaserelated pages 9-10): Thomas Leung, Xiang-Qun Chen, Ivan Tan, Edward Manser, and Louis Lim. Myotonic dystrophy kinase-related cdc42-binding kinase acts as a cdc42 effector in promoting cytoskeletal reorganization. Molecular and Cellular Biology, 18:130-140, Jan 1998. URL: https://doi.org/10.1128/mcb.18.1.130, doi:10.1128/mcb.18.1.130. This article has 373 citations and is from a domain leading peer-reviewed journal.

17. (unbekandt2014anovelsmallmolecule pages 10-11): Mathieu Unbekandt, Daniel R Croft, Diane Crighton, Mokdad Mezna, Duncan McArthur, Patricia McConnell, Alexander W Schüttelkopf, Simone Belshaw, Andrew Pannifer, Mairi Sime, Justin Bower, Martin Drysdale, and Michael F Olson. A novel small-molecule mrck inhibitor blocks cancer cell invasion. Cell Communication and Signaling, Oct 2014. URL: https://doi.org/10.1186/s12964-014-0054-x, doi:10.1186/s12964-014-0054-x. This article has 73 citations and is from a peer-reviewed journal.

18. (unbekandt2014anovelsmallmolecule pages 14-15): Mathieu Unbekandt, Daniel R Croft, Diane Crighton, Mokdad Mezna, Duncan McArthur, Patricia McConnell, Alexander W Schüttelkopf, Simone Belshaw, Andrew Pannifer, Mairi Sime, Justin Bower, Martin Drysdale, and Michael F Olson. A novel small-molecule mrck inhibitor blocks cancer cell invasion. Cell Communication and Signaling, Oct 2014. URL: https://doi.org/10.1186/s12964-014-0054-x, doi:10.1186/s12964-014-0054-x. This article has 73 citations and is from a peer-reviewed journal.

19. (unbekandt2014anovelsmallmolecule pages 7-10): Mathieu Unbekandt, Daniel R Croft, Diane Crighton, Mokdad Mezna, Duncan McArthur, Patricia McConnell, Alexander W Schüttelkopf, Simone Belshaw, Andrew Pannifer, Mairi Sime, Justin Bower, Martin Drysdale, and Michael F Olson. A novel small-molecule mrck inhibitor blocks cancer cell invasion. Cell Communication and Signaling, Oct 2014. URL: https://doi.org/10.1186/s12964-014-0054-x, doi:10.1186/s12964-014-0054-x. This article has 73 citations and is from a peer-reviewed journal.

20. (unbekandt2020thecdc42effector pages 1-3): Mathieu Unbekandt, Sergio Lilla, Sara Zanivan, and Michael F. Olson. The cdc42 effector protein mrckβ autophosphorylates on threonine 1108. Small GTPases, 11:451-460, Jan 2020. URL: https://doi.org/10.1080/21541248.2018.1564472, doi:10.1080/21541248.2018.1564472. This article has 6 citations and is from a peer-reviewed journal.

21. (unbekandt2020thecdc42effector pages 3-4): Mathieu Unbekandt, Sergio Lilla, Sara Zanivan, and Michael F. Olson. The cdc42 effector protein mrckβ autophosphorylates on threonine 1108. Small GTPases, 11:451-460, Jan 2020. URL: https://doi.org/10.1080/21541248.2018.1564472, doi:10.1080/21541248.2018.1564472. This article has 6 citations and is from a peer-reviewed journal.

22. (unbekandt2020thecdc42effector pages 4-7): Mathieu Unbekandt, Sergio Lilla, Sara Zanivan, and Michael F. Olson. The cdc42 effector protein mrckβ autophosphorylates on threonine 1108. Small GTPases, 11:451-460, Jan 2020. URL: https://doi.org/10.1080/21541248.2018.1564472, doi:10.1080/21541248.2018.1564472. This article has 6 citations and is from a peer-reviewed journal.

23. (unbekandt2020thecdc42effector pages 7-9): Mathieu Unbekandt, Sergio Lilla, Sara Zanivan, and Michael F. Olson. The cdc42 effector protein mrckβ autophosphorylates on threonine 1108. Small GTPases, 11:451-460, Jan 2020. URL: https://doi.org/10.1080/21541248.2018.1564472, doi:10.1080/21541248.2018.1564472. This article has 6 citations and is from a peer-reviewed journal.

24. (unbekandt2020thecdc42effector pages 9-10): Mathieu Unbekandt, Sergio Lilla, Sara Zanivan, and Michael F. Olson. The cdc42 effector protein mrckβ autophosphorylates on threonine 1108. Small GTPases, 11:451-460, Jan 2020. URL: https://doi.org/10.1080/21541248.2018.1564472, doi:10.1080/21541248.2018.1564472. This article has 6 citations and is from a peer-reviewed journal.

25. (zhao2015myotonicdystrophykinaserelated pages 3-4): Zhuo-shen Zhao and E. Manser. Myotonic dystrophy kinase-related cdc42-binding kinases (mrck), the rock-like effectors of cdc42 and rac1. Small GTPases, 6:81-88, Apr 2015. URL: https://doi.org/10.1080/21541248.2014.1000699, doi:10.1080/21541248.2014.1000699. This article has 78 citations and is from a peer-reviewed journal.

26. (zhao2015myotonicdystrophykinaserelated pages 7-7): Zhuo-shen Zhao and E. Manser. Myotonic dystrophy kinase-related cdc42-binding kinases (mrck), the rock-like effectors of cdc42 and rac1. Small GTPases, 6:81-88, Apr 2015. URL: https://doi.org/10.1080/21541248.2014.1000699, doi:10.1080/21541248.2014.1000699. This article has 78 citations and is from a peer-reviewed journal.

27. (zihni2021mrckamaster pages 1-4): Ceniz Zihni. Mrck: a master regulator of tissue remodeling or another ‘rock’ in the epithelial block? Tissue Barriers, May 2021. URL: https://doi.org/10.1080/21688370.2021.1916380, doi:10.1080/21688370.2021.1916380. This article has 7 citations.

28. (zihni2021mrckamaster pages 4-6): Ceniz Zihni. Mrck: a master regulator of tissue remodeling or another ‘rock’ in the epithelial block? Tissue Barriers, May 2021. URL: https://doi.org/10.1080/21688370.2021.1916380, doi:10.1080/21688370.2021.1916380. This article has 7 citations.

29. (zihni2021mrckamaster pages 6-8): Ceniz Zihni. Mrck: a master regulator of tissue remodeling or another ‘rock’ in the epithelial block? Tissue Barriers, May 2021. URL: https://doi.org/10.1080/21688370.2021.1916380, doi:10.1080/21688370.2021.1916380. This article has 7 citations.

30. (clayton2020targetingrhogtpase pages 12-12): Natasha S. Clayton and Anne J. Ridley. Targeting rho gtpase signaling networks in cancer. Frontiers in Cell and Developmental Biology, Apr 2020. URL: https://doi.org/10.3389/fcell.2020.00222, doi:10.3389/fcell.2020.00222. This article has 183 citations and is from a peer-reviewed journal.

31. (elkins2009structureofdystrophia pages 1-2): Jonathan M. Elkins, Ann Amos, Frank H. Niesen, Ashley C.W. Pike, Oleg Fedorov, and Stefan Knapp. Structure of dystrophia myotonica protein kinase. Protein Science, Apr 2009. URL: https://doi.org/10.1002/pro.82, doi:10.1002/pro.82. This article has 26 citations and is from a peer-reviewed journal.

32. (garcia2006molecularinsightsinto pages 68-72): Molecular insights into the regulatory interactions of Dystrophia myotonica protein kinase

33. (prudnikova2015molecularpathwaystargeting pages 1-3): Tatiana Y. Prudnikova, Sonali J. Rawat, and Jonathan Chernoff. Molecular pathways: targeting the kinase effectors of rho-family gtpases. Clinical Cancer Research, 21:24-29, Jan 2015. URL: https://doi.org/10.1158/1078-0432.ccr-14-0827, doi:10.1158/1078-0432.ccr-14-0827. This article has 73 citations and is from a highest quality peer-reviewed journal.

34. (prudnikova2015molecularpathwaystargeting pages 9-11): Tatiana Y. Prudnikova, Sonali J. Rawat, and Jonathan Chernoff. Molecular pathways: targeting the kinase effectors of rho-family gtpases. Clinical Cancer Research, 21:24-29, Jan 2015. URL: https://doi.org/10.1158/1078-0432.ccr-14-0827, doi:10.1158/1078-0432.ccr-14-0827. This article has 73 citations and is from a highest quality peer-reviewed journal.

35. (wansink2003alternativesplicingcontrols pages 1-2): Derick G. Wansink, René E. M. A. van Herpen, Marga M. Coerwinkel-Driessen, Patricia J. T. A. Groenen, Brian A. Hemmings, and Bé Wieringa. Alternative splicing controls myotonic dystrophy protein kinase structure, enzymatic activity, and subcellular localization. Molecular and Cellular Biology, 23:5489-5501, Aug 2003. URL: https://doi.org/10.1128/mcb.23.16.5489-5501.2003, doi:10.1128/mcb.23.16.5489-5501.2003. This article has 87 citations and is from a domain leading peer-reviewed journal.

36. (zihni2021mrckamaster pages 8-9): Ceniz Zihni. Mrck: a master regulator of tissue remodeling or another ‘rock’ in the epithelial block? Tissue Barriers, May 2021. URL: https://doi.org/10.1080/21688370.2021.1916380, doi:10.1080/21688370.2021.1916380. This article has 7 citations.